Innovation is accelerating. Not just in communications, computer technology and artificial intelligence but also in medical science, including therapies for people with inherited bleeding disorders.
The last decade has seen significant treatment advances with the introduction of extended half-life factor VIII and IX concentrates and factor VIII mimetics like emicizumab. The first gene therapies have been introduced for both hemophilia A and B. The first rebalancing agents have been approved by health authorities. But those are just the start. Several different approaches to preventing and managing bleeding are in different stages of development, not only for hemophilia but also for von Willebrand disease and rare bleeding disorders that historically have received less research attention.
The goal of the CHS Novel Therapies Education Program is to provide people with bleeding disorders and their caregivers a basic understanding of novel therapies. This will help in shared decision-making with their health care providers when discussing and making treatment choices.
It will include many components, starting with a comprehensive booklet which you can access below.
This online booklet, All About Novel Therapies, is a guide to emerging therapies.
Its goal is to provide a basic understanding of novel therapies. As treatment options are changing at a rapid pace, this booklet will be regularly updated. Stay tuned!
ALL ABOUT NOVEL THERAPIES
Welcome to our new podcast series entitled NOVEL THERAPIES FOR BLEEDING DISORDERS, produced by the Canadian Hemophilia Society. The series explores therapies that are potentially coming to the Canadian market for the treatment of hemophilia A and B, von Willebrand disease and other rare bleeding disorders such as Glanzmann Thrombasthenia. Our guide to these new therapies is DR. ROY KHALIFÉ, Assistant Professor at the University of Ottawa and co-director of the Ottawa Regional Adult Bleeding Disorders Program at the Ottawa Hospital.
ALL PODCASTS ARE AVAILABLE IN VIDEO AND AUDIO FORMATS.
In this episode, DR. ROY KHALIFÉ will talk about therapies that may become available in the future to treat von Willebrand disease and Glanzmann Thrombasthenia.
CLICK HERE to access the episode entitled “What’s coming for VWD and Glanzmann Thrombasthenia?”
In this first episode, DR. ROY KHALIFÉ talks about therapies for various bleeding disorders that have the potential to be available in Canada in the next couple of years.
CLICK HERE to access the episode entitled “The potential next therapies for bleeding disorders to enter the Canadian market”
The CHS Novel Therapies Education Program is made possible by unrestricted grants from NOVO NORDISK, PFIZER CANADA and SANOFI to the Canadian Hemophilia Society.
